达雷妥尤单抗联合方案在复发难治多发性骨髓瘤中持续MRD阴性的评估:POLLUX和CASTOR分析
该分析基于POLLUX和CASTOR研究,评估达雷妥尤单抗联合方案治疗复发难治多发性骨髓瘤的持续MRD阴性率。中位随访54.8和50.2个月,ITT人群中D-Rd和D-Vd的MRD阴性率分别显著高于Rd和Vd。持续MRD阴性与无进展生存期延长相关。
要点
- D-Rd较Rd显著提高ITT人群持续≥6个月MRD阴性率(20.3% vs 2.1%)。
- D-Vd较Vd显著提高持续≥12个月MRD阴性率(6.8% vs 0%)。
- 持续MRD阴性与更长的无进展生存期相关。
核心结论
- 达雷妥尤单抗联合方案较标准治疗诱导更高的持续MRD阴性率,与持久缓解和临床结局延长相关。
研究设计与样本
- 基于POLLUX和CASTOR两项研究的事后分析,评估持续MRD阴性与结局。
- MRD采用二代测序(灵敏度10^-5)在疑似CR、确认CR后3和6个月(POLLUX)、首次给药后6和12个月(CASTOR)及CR后每12个月检测。
主要发现
- POLLUX中位随访54.8个月,CASTOR为50.2个月。
- ITT人群中,D-Rd vs Rd的MRD阴性率为32.5% vs 6.7%,D-Vd vs Vd为15.1% vs 1.6%(均P<.0001)。
- ≥CR患者中,POLLUX的MRD阴性率D-Rd 57.4% vs Rd 29.2%(P=.0001),CASTOR的D-Vd 52.8% vs Vd 17.4%(P=.0035)。
- ITT人群中,持续≥6个月MRD阴性率D-Rd vs Rd为20.3% vs 2.1%,D-Vd vs Vd为10.4% vs 1.2%(均P<.0001);持续≥12个月D-Rd vs Rd为16.1% vs 1.4%(P<.0001),D-Vd vs Vd为6.8% vs 0%。
- ≥CR患者中持续MRD阴性结果相似,且更多达雷妥尤单抗组患者达到MRD阴性和持续MRD阴性,与无进展生存期延长相关。
关键数值与推荐
- MRD阴性定义为二代测序检测灵敏度10^-5。
- 持续MRD阴性定义为≥6个月或≥12个月。
临床怎么用
- 在复发难治多发性骨髓瘤中,达雷妥尤单抗联合方案可提高持续MRD阴性率,支持其临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies. METHODS: MRD was assessed via next-generation sequencing (10-5) at suspected complete response (CR), 3 and 6 months following confirmed CR (POLLUX), 6 and 12 months following the first dose (CASTOR), and every 12 months post-CR in both studies. Sustained MRD negativity (≥ 6 or ≥ 12 months) was evaluated in the intention-to-treat (ITT) and ≥ CR populations. RESULTS: The median follow-up was 54.8 months in POLLUX and 50.2 months in CASTOR. In the ITT population, MRD-negativity rates were 32.5% versus 6.7% for D-Rd versus lenalidomide and dexamethasone (Rd) and 15.1% versus 1.6% for D-Vd versus bortezomib and dexamethasone (Vd; both P < .0001). Higher MRD negativity rates were achieved in ≥ CR patients in POLLUX (D-Rd, 57.4%; Rd, 29.2%; P = .0001) and CASTOR (D-Vd, 52.8%; Vd, 17.4%; P = .0035). More patients in the ITT population achieved sustained MRD negativity ≥ 6 months with D-Rd versus Rd (20.3% v 2.1%; P < .0001) and D-Vd versus Vd (10.4% v 1.2%; P < .0001), and ≥ 12 months with D-Rd versus Rd (16.1% v 1.4%; P < .0001) and D-Vd versus Vd (6.8% v 0%). Similar results for sustained MRD negativity were observed among ≥ CR patients. More patients in the daratumumab-containing arms achieved MRD negativity and sustained MRD negativity, which were associated with prolonged progression-free survival. CONCLUSION: Daratumumab-based combinations induce higher rates of sustained MRD negativity versus standard of care, which are associated with durable remissions and prolonged clinical outcomes.
引用
- Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021. PMID: 33513030. doi:10.1200/JCO.20.01814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。